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Abstract
Background: Endothelial dysfunction (ED) is functionally characterized by decreased
vasorelaxation, increased thrombosis, increased inflammation, and altered angiogenic potential, has
been intimately associated with the progression and severity of cardiovascular disease. Patients
with compromised cardiac function oftentimes have a state of chronic mild decreased oxygen at
the level of the vasculature and organs, which has been shown to exacerbate ED. Hypoxia inducible
factor (HIF) is a transcription factor complex shown to be the master regulator of the cellular
response to decreased oxygen levels and many HIF target genes have been shown to be associated
with ED.
Methods: Human endothelial and aortic smooth muscle cells were exposed either to A) normoxia
(21% O2) for three weeks, or to B) mild decreased oxygen (15% O2) for three weeks to mimic
blood oxygen levels in patients with heart failure, or to C) mild decreased oxygen for two weeks
followed by one week of normoxia ("memory" treatment). Levels of HIF signaling genes (HIF-1α,
HIF-2α, VEGF, BNIP3, GLUT-1, PAI-1 and iNOS) were measured both at the protein and mRNA
levels.
Results: It was found that chronic exposure to mild decreased oxygen resulted in significantly
increased HIF signaling. There was also a "memory" of HIF-1α and HIF target gene induction when
oxygen levels were normalized for one week, and this "memory" could be interrupted by adding a
small molecule HIF inhibitor to the last week of normalized oxygen. Finally, levels of ubiquitylated
HIF-1α were reduced in response to chronic mild decreased oxygen and were not full restored
after oxygen normalization.
Conclusion: These data suggest that HIF signaling may be contributing to the pathogenesis of
endothelial dysfunction and that normalization of oxygen levels may not be enough to reduce
vascular stress.
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Endothelial dysfunction has been shown to play a causa-
tive role in atherosclerosis [1], ischemic heart disease [2],
coronary artery disease [3], peripheral neuropathy [4],
diabetic cardiomyopathy [5], erectile dysfunction [6] and
even ischemia/reperfusion subsequent to myocardial inf-
arction [7]. Endothelial dysfunction is a generalized syn-
drome characterized by attenuated vasodilation [8], due
at least in part to decreased available nitric oxide (NO)
[9], a concomitant buildup of reactive species [10] and
stimulation of vascular stress pathways [11]. Another
characteristic of endothelial dysfunction is an altered ang-
iogenic response [12], which can affect tissue vascularity,
immune cell infiltration, blood flow patterns, and wound
healing (reviewed in [11]). If the blood vessels cannot
supply the tissues with blood, a state of relative decreased
oxygen ensues further contributing to endothelial dys-
function [13].
Hypoxia induces expression of hypoxia inducible factor
(HIF), a transcription factor complex shown to be the
master regulator of the cellular response to decreased oxy-
gen levels [14]. The HIF proteins belong to a family of
basic helix-loop-helix transcription factors. The HIF com-
plex is a heterodimer consisting of a regulated α subunit
and a constitutive β subunit [15]. In normoxic environ-
ments, the α subunit is hydroxylated at proline residues
[16], which targets it for ubiquitylation, by proteins such
as Von Hippel-Lindau [17], ultimately resulting in its deg-
radation by the proteasome. There are two known HIF α
subunits which stimulate transcription, HIF-1α and HIF-
2α, in addition to a third α subunit (HIF-3α) lacking the
DNA binding domain which appears to compete with
HIF-1α and HIF-2α for β subunit binding and acts to
inhibit HIF signaling [18]. The HIF-1α/HIF-1β het-
erodimer binds to hypoxia response elements in the regu-
latory regions of more than 70 target genes such as the
vascular endothelial growth factor (VEGF), plasminogen
activator inhibitor (PAI-1), inducible nitric oxide synthase
(iNOS), erythropoietin, Bcl2/adenovirus EIB 19kD-inter-
acting protein 3 (BNIP3), heme oxygenase-1, and glucose
transporter-1 (GLUT-1) [19]. In addition to being regu-
lated by hypoxia, the HIF pathway can be modulated by
reactive species [20,21], nitric oxide [22], metals [23,24],
cytokines [25], and growth factor signaling through phos-
phatidylinositol 3-kinase [26] and mitogen activated pro-
tein (MAP) kinase pathways [27].
The idea that vascular stress has long-lasting effects that
perpetuate further damage, even when the stressor is
removed, is developing support both in the laboratory
[28] and in the clinic [[29-32] 364, 771-7]. For example,
it was found that changes in cellular fatty acid metabolism
persist for up to 30 hours after oxygen levels are normal-
ized following myocardial ischemia [31]. Clinically, per-
sistent benefits of antihypercholesterolemic agents [32]
angiotensin converting enzyme (ACE) inhibitors [33],
and insulin- and drug-mediated glucose normalization in
diabetic patients [29,30] have been observed long after
these agents were discontinued, further supporting a what
has been termed a "memory" of vascular stress.
The first goal of this paper was to determine whether
chronic exposure to mild decreased oxygen (15% O2)
induces the HIF signaling system in blood vessels. The sec-
ond goal was to examine whether there was a "memory"
of HIF signaling induction long after oxygen levels were
normalized. To investigate these novel questions, human
endothelial and aortic smooth muscle cells were exposed
either to A) normoxia (21% O2) for three weeks, or to B)
mild decreased oxygen (15% O2) for three weeks, or to C)
mild decreased oxygen for two weeks followed by one
week of normoxia ("memory" treatment). Levels of HIF
signaling genes (HIF-1α, HIF-2α, VEGF, BNIP3, GLUT-1,
PAI-1 and iNOS) were measured at the protein and mRNA
levels. It was found that chronic exposure to mild
decreased oxygen resulted in significantly increased HIF
signaling. There was also a "memory" of HIF-1α protein
and of several HIF target genes when oxygen levels were
normalized for one week after two weeks of mild
decreased oxygen, and this "memory" could be inter-
rupted by adding a chemical HIF inhibitor to the last week
of normalized oxygen. Finally, levels of ubiquitylated
HIF-1α were reduced in response to chronic mild
decreased oxygen and were not full restored after oxygen
normalization. Taken together, these data suggest a
"memory" of HIF signaling through HIF-1α in the
endothelium in response to chronic mild decreased oxy-
gen and point out the need for more aggressive vascular
drug therapies for overcoming the vascular "memory"
stress response.
Methods
Chemicals and cell culture reagents
All chemicals were purchased from EMD Biosciences (San
Diego, CA) unless otherwise noted. Cell culture reagents
were purchased from Invitrogen (Carlsbad, CA). Inhibi-
tors were purchased from EMD Bioscience except oxypu-
rinol and ALA, which were from Sigma Chemical and the
UCP2 adenovirus, which was a kind gift of Dr. Ming-Hui
Zou in Dept. of Endocrinology at OUHSC.
Cell culture
HMEC-1 human microvascular endothelial cells [34]
(obtained from the Centers for Disease Control) were
grown in MCDB-131 (pH 7.5 ± 0.3) media supplemented
with 15% Cosmic Calf Serum (Hyclone, Logan, UT), 2
mM sodium pyruvate, 2 mM glutamine (Mediatech,
Herndon, VA) and penicillin/streptomycin (Hyclone,
Logan, UT), 10 ng/ml EGF (Peprotech, Rocky Hill, NJ),Page 2 of 13
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with 5% carbon dioxide added. HUVEC (human umbili-
cal vein endothelial cells) and ASMC (human aortic vas-
cular smooth muscle cells) (Cambrex, North Brunswick,
NJ) were grown in Media-199 (Mediatech, Herndon, VA)
supplemented with 15% Cosmic Calf Serum (Hyclone,
Logan, UT), 2 mM sodium pyruvate, 2 mM glutamine
(Mediatech, Herndon, VA), penicillin/streptomycin
(Hyclone, Logan, UT), 1% MEM Vitamins (Invitrogen
Carlsbad, CA) and 1% MEM Non-essential Amino Acids
(Invitrogen Carlsbad, CA) in a humidified environment
with 5% carbon dioxide added. Cells were incubated with
5 mM glucose (with 25 mM mannitol for osmolarity nor-
malization). Decreased oxygen levels were achieved using
a 3-gas incubator (NuAire, Plymouth, MN) and cells fed
and passaged in decreased oxygen using a hypoxic glove
box (Coy, Ann Arbor, MI). As a control for HIF stimula-
tion, cells were exposed for 4 hr to 2.5% O2 [35] or to 100μM deferoxamine for 4 hr [36]. The last week of normoxia
was given with or without 62.5 μM α-lipoic acid (ALA)
[37], or with or without 10 μM apocynin [38], or with or
without 1 mM L-NAME [39], or with or without 10 μM
oxypurinol [39], or with or without 5 μM YC-1 [40], or
with or without 25–100 plaque-forming units (PFU)/cell
of an UCP2 overexpressing adenovirus [41]. Inhibitors
were replaced every other day and 24 hours before the end
of the experiment. Cells were grown at 25–30% conflu-
ence in 25 or 75 cm2 flasks until 100% confluent.
Adenoviral siRNA constructs
Sequences for the three HIF-1α small hairpin interfering
RNAs are previously published [42-44]. Sequences were
synthesized by the OUHSC molecular biology resource
facility and ligated first into a shuttle vector (pShuttle-
CMV, Stratagene, Cedar Creek TX) and then into an aden-
oviral vector (pAdEasy-1, Stratagene, Cedar Creek TX),
cotransformed into competent bacterial cells containing
adenoviral plasmid (BJ1583, Stratagene, Cedar Creek TX),
linearized and transfected into HEK293 competent cells
(Stratagene, Cedar Creek TX). Adenoviral titer was deter-
mined by a plaque agarose assay and 50–100 PFU/cells of
each virus in serum-free media for 2 hr then serum-con-
taining media replaced. Cells were re-treated every 3 days.
CFDA-AM cell proliferation assay
After treatment, 5 μM 5-carboxyfluorescein diacetate ace-
toxymethyl ester (CFDA-AM; Molecular Probes, Eugene,
OR), a substrate cleaved multiple times by non-specific
cellular esterases to form fluorescein, was added for 1 h at
37°C. The fluorescence was read on a plate reader (BMG
Labtech, Durham, NC) using the fluorescein channel as a
marker of cell proliferation [45]. Data were then graphed
as a percent of the fluorescence of untreated or normoxic
cells.
Co-immunoprecipitation and Western blot
Cell lysates (100 μg) were immunoprecipitated using an
antibody against HIF-1α (2 μg/100 μg of sample protein)
(anti-rabbit, Chemicon, Littleton, CO) and subjected to
SDS-PAGE, transferred to nitrocellulose and immunob-
lotted for ubiquitin (Ubiquitin anti-rabbit 1:1500,
Abcam, Cambrige, MA), and immmunoblotted against
HIF-1α (anti-mouse, 1:100, Abcam H1alpha67, Cam-
brige, MA) used as a control for immunoprecipitation.
Equal amounts of cell lysates (20–50 μg) were resolved
using 8–12% SDS-PAGE gels, transferred to 0.2 μm nitro-
cellulose (Schleicher and Schuell), blocked in SuperBlock
(Pierce Chemical), incubated with primary antibodies
overnight at 4°C or for 2 hours at room temperature,
washed three times in Tris-buffered saline with 0.25%
Tween-20 (TBST), appropriate secondary antibodies anti-
mouse or anti-rabbit HRP-conjugates (Pierce) diluted in
StartingBlock (TBS) Blocking Buffer added at 1:25,000
dilution for 1 hr at RT, washed three times with TBST,
SuperSignal Dura chemiluminescence substrate (Pierce
Chemical) added, and digital images captured using a
charge-coupled device (CCD) camera (Kodak Image Sta-
tion 4000). Primary antibodies and dilutions used were as
follows: anti-HIF-1α(Chemicon: 1:500), anti-HIF-2α
(Santa Cruz Biotechnology: 1:500), anti-Glut-1 (Santa
Cruz Biotechnology: 1:150), anti-iNOS (Upstate Biotech-
nology, Lake Placid, NY: 1:500), anti-BNIP3 (Abgent, San
Diego, CA 1:100), anti-PAI-1 (Santa Cruz Biotechnology:
1:150)). Densitometry of bands was done using Image J
1.30 analysis software capturing integrated density of
regions of interest and dividing these values by the unit
area of the region of interest. In all cases, confirmation of
equal loading was accomplished by Memcode staining
(Pierce Chemical) and by probing blots against vinculin
(1:4,000 Sigma).
RNA Extraction and Quantitative Real-Time RT-PCR
Total RNA was extracted from the control and treated
HMEC-1 cells using the RNeasy kit (QIAGEN) immedi-
ately following the treatments. The concentration and
purity of RNA samples were determined spectrophoto-
metrically by absorbance at 260 and 280 nm, and the
integrity was confirmed by agarose gel electrophoresis.
Synthesis of the first strand cDNAs, quantitative real-time
PCR reactions and data analysis were then performed.
Total RNA (1 μg) was reverse transcribed in 50 μl reaction
and 5 μl of cDNA was then used for PCR reaction accord-
ing to Invitrogen technical manual.
The following gene-specific primer pairs were used: hif-1α,
forward; 5'-CTGATATTAAACCTAAATGTTCTGCCTACC-
3', reverse; 5'-CAGTCTGCTCAAAATAT CTTTATACCAAC-
3'; glut-1, forward 5'-CCTAAGGATCTCTCAGGAG-
CACAG-3', reverse; 5'-TCAGGTTTGGAAGTCTCATCCAG-Page 3 of 13
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3', reverse; 5'-TCAGGATCTGAGTGGGAACATTC-3', hif-
2α, forward 5'-GCGGCCGCTCACTTGTCATCGTCGTC-
CTTGTAGTCGGTGGCCTGGT-3', reverse; 5'-
ACCAGGCCACCGACTACAAGGACGACGATGACAAGT-
GAGCGGCCGC-3', iNOS, forward, 5'- TACTCCAC-
CAACAATGGCAA-3', reverse, 5'-
GATGAGCTGAGCATTCCACA-3', hprt, forward 5'-
GGGAGGCCATCACATTGTAG-3', reverse, 5'-CCTGAC-
CAAGGAAAGCAAAG-3'. Gene expression of HIF-1α, HIF-
2α, iNOS, Glut-1, and VEGF were quantified relative to
the expression level of HPRT, a housekeeping gene.
Probes for these reactions were purchased from Invitrogen
(Carlsbad, CA). The difference in threshold number of
cycles between the gene of interest and HPRT was then cal-
culated and plotted as relative abundance of gene of inter-
est over HPRT.
VEGF ELISA
VEGF levels were assessed by ELISA using a rabbit polyclo-
nal anti-VEGF antibody (Abcam, Cambridge, MA). Super-
natants from cells (100 μl) were added to a high binding
white ELISA plate (COSTAR, Corning, NY) together with
a standard curve of recombinant human VEGF (0.1 –
10,000 pg/ml) (Biosource International, Camarillo, CA)
overnight at 4°C. The wells were washed with TBS,
blocked with 1% BSA in TBS before anti-VEGF antibody
was (1:1000 dilution of 1 mg/ml stock) added for 2 hours
at RT, the wells washed again and 1:2000 anti-Rabbit HRP
conjugate (Pierce, Rockford, IL) added for 45 minutes at
RT, the wells washed again with TBS, then an ECL ELISA
substrate (Pierce) added to wells for 5 minutes and the
chemiluminescence measured using a plate reader (Fluos-
tar Optima, BMG Labtechnologies, NC). Data were nor-
malized to the standard curve to yield values in pg/ml
VEGF and graphed as percentage of untreated control.
Statistics
Data were analyzed using one-way analysis of variance to
compare the means of all the groups. The Neuman-Keuls
multiple comparisons procedure was used to determine
which pairs of means were different. Differences were con-
sidered significant at P < 0.05.
Results
Chronic mild decreased oxygen induces the HIF pathway
Human microvascular endothelial cells (HMEC-1) were
exposed to either 21% O2 (normoxia) or to 5%, 7.5% and
10 and 15% O2 for three weeks (Figure 1). Oxygen levels
lower than 15% O2 were found to result in significant
decreases in endothelial cell proliferation (Figure 2). Since
the goal of this paper was to examine the effect of mild
Treatment scheme for experiments in this workFigure 1
Treatment scheme for experiments in this work. Isolated microvascular endothelial cells mild decreased oxygen (15% 
O2) for three weeks (I) or to mild decreased oxygen for two weeks then to normoxia for one week ("memory" treatment – II).Page 4 of 13
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the studies. This level of decreased oxygen is very mild in
comparison with arterial oxygen levels of patients with
chronic obstructive pulmonary disease [46,47], sleep
apnea [48], or coronary artery disease [49].
Levels of HIF signaling proteins (Figure 3) and steady-
state mRNA (Figure 4) were measured by Western blot
and real-time RT-PCR, respectively. For each protein or
mRNA graph, representative Western blots (for protein
except for VEGF in which an ELISA was used) or RNA gels
(for mRNA) are shown above graphs of densitometric
analysis of bands. We found that protein levels of HIF-1α
and HIF-2α and of the HIF target genes GLUT-1 [50],
BNIP3 [51], PAI-1 [52], iNOS [53], and VEGF [54] were
induced in response to chronic mild decreased oxygen
(Figure 3A–G; "D" compared to "N"), although this
induction was not as profound as that of the cells in
response to acute hypoxia (2.5% O2 for 4 hours; Figure
3A–G; ("AH")). In contrast, little effect was observed on
the constitutively regulated loading protein vinculin (Fig-
ure 3H). It was next found that there was no changes in
HIF-1α (Figure 4A) mRNA levels in response to chronic
mild decreased oxygen, but that mRNA levels of the HIF
target genes VEGF (Figure 4B), GLUT-1 (Figure 4C), and
iNOS (Figure 4D) were induced as compared to normoxic
controls.
HIF induction persists after oxygen normalization
To determine whether the induction of HIF signaling per-
sists after oxygen levels are normalized, cells were exposed
to two weeks of mild decreased oxygen followed by one
week of normoxia. Unexpectedly, levels of HIF-1α protein
(Figure 3A) but not HIF-1α mRNA (Figure 4A) remained
induced one week after normalization. There was no
"memory" of HIF-2α protein induction (Figure 3B) but
there was a "memory" of induction of the HIF target genes
GLUT-1 (Figure 3C), BNIP3 (Figure 3D), PAI-1 (Figure
3E), iNOS (Figure 3F) and VEGF (Figure 3G) at the pro-
tein level. This "memory" of induction was also observed
for VEGF (Figure 4B), GLUT-1 (Figure 4C) and iNOS (Fig-
ure 4D) at the mRNA level.
The "memory" of HIF signaling after oxygen normalization 
is not cell specific
To determine whether this "memory" of HIF induction
was unique to the HMEC-1 cells, which harbor an SV40 T
antigen [34], primary human umbilical vein endothelial
cells (HUVECs) and human aortic vascular smooth mus-
cle cells (ASMCs) were exposed to the same treatments as
the HMEC-1 cells. Like the HMEC-1s, both an induction
of HIF-1α (Figure 5A, 5E) and the HIF target genes VEGF
(Figure 5C, 5G) and GLUT-1 (Figure 5D, 5H) and a
"memory" of that induction was observed at the protein
level in both the HUVECs and ASMCs. Interestingly, an
absence of induction of HIF-2α was observed in the
HUVECs (Figure 5B) but not in the ASMCs (Figure 5F).
HIF mediates in the persistent induction of VEGF, BNIP3, 
PAI-1 and iNOS after oxygen normalization
It has been suggested that a major regulator of HIF signal-
ing in response to mild decreased oxygen is not the oxy-
gen levels themselves, but rather a cellular buildup of
reactive species secondary to decreased oxygen [55]. To
address this, HIF and reactive species inhibitors were
added during the last week of normoxia subsequent to
two weeks of mild decreased oxygen in the HUVECs. The
rationale for adding agents during the normalization
period is to mimic a clinical situation with a patient with
previous decreased oxygen exposure. To reduce HIF levels,
short hairpin RNAs (hrRNAs) against HIF were developed.
Adenoviral delivery of these siRNAs was found to reduce
HIF-1α protein expression by 80–90% (Figure 6A).
Unfortunately, all of these HIF shRNAs were found to be
toxic to the cells (Figure 6B). In place of genetic manipu-
lations, a well-characterized pharmacological agent, YC-1
[40], known to degrade the HIF-1α protein [56] was cho-
sen and doses titrated to minimize cell death. It was found
that 5 μM YC-1 resulted in approximately 60% reduction
in the "memory" of induction of HIF-1α (Figure 7A) but
not HIF-2α (Figure 7B) proteins with no significant toxic-
ity to the cells (Figure 6B). YC-1 also resulted in a similar
level of reduction in the "memory" of induction of the
HIF target genes VEGF (Figure 7C), BNIP3 (Figure 7D),
PAI-1 (Figure 7E) and iNOS (Figure 7F), but not GLUT-1
(Figure 7G) at the protein level.
Effect of chronic relative hypoxia on a marker of cell prolifer-ation in HMEC-1 cellsFigure 2
Effect of chronic relative hypoxia on a marker of cell 
proliferation in HMEC-1 cells. HMEC-1 cells were 
exposed to normoxia (20% O2) or to various levels of rela-
tive hypoxia for 3 weeks followed by a one hour incubation 
with 5 μM CFDA-AM and fluorescence measurement as in 
methods. The data represent the mean +/- SEM of triplicate 
wells from 3 independent experiments. ** = P < 0.01 and *** 
= P < 0.001 using one-way ANOVA with a Neuman-Keuls 
multiple comparisons post-test.Page 5 of 13
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Effect of oxygen normalization on HIF-1α, HIF-2α, Glut-1, BNIP3, PAI-1, iNOS and VEGF protein expression 
in human endothelial cells. Human microvascular endothelial cells were exposed as described in Figure 1. Western blots 
were performed against HIF-1α (A), HIF-2α (B), Glut-1 (C), BNIP3 (D), PAI-1 (E), iNOS (F) on cellular lysates and ELISA was 
performed against VEGF (G) on cellular supernatants. Graphs indicate the densitometric analysis relative to the respective nor-
moxic protein expression (dashed line) with a representative blot for each protein above each graph. Acute hypoxia (2.5%02; 4 
hours) ("AH") was used as a positive control for the induction of proteins. Data in graphs represent the mean +/- S.E.M. from 
three separate experiments with a total sample size of 4–6. Asterisk, P < 0.05; double asterisk, P < 0.01; triple asterisk, P < 
0.001 as compared to cells incubated in normoxia for three weeks.
Reactive species mediate the persistent induction of 
GLUT-1 after oxygen normalization
To determine whether reactive species, a key non-hypoxic
regulator of signaling [55], was involved in the "memory"
of HIF signaling after oxygen normalization, the general
antioxidant α-lipoic acid (ALA) [58] was added to the last
week of normoxia. No change in the persistent induction
of HIF-1α (Figure 7A), HIF-2α (Figure 7B), BNIP3 (Figure
7D), PAI-1 (Figure 7E), or iNOS (Figure 7F) proteins was
observed with the addition of ALA. In contrast, a signifi-
cant reduction in the persistent induction of GLUT-1 pro-
tein (Figure 7G) was observed with ALA. To examine the
source of the reactive species which leading to the "mem-
ory" of GLUT-1 induction, the mitochondrial respiratory
chain uncoupling protein UCP2; or the NAD(P)H oxidase
inhibitor apocynin (APO); or oxypurinol (OXY), a xan-
thine oxidoreductase inhibitor; or L-NAME, an NOS
inhibitor; were added during the last week of normalizedPage 6 of 13
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Effect of oxygen normalization on HIF target mRNA expression in human endothelial cells. Human microvascular 
endothelial cells were exposed as described in Figure 1. Total RNA was extracted and the amount of HIF-1α (A), VEGF (B), 
Glut-1 (C), and iNOS (D) transcripts were analyzed by quantitative real-time RT-PCR as described in Materials and Methods. 
In the graphs (bottom panels), all values are expressed relative to the HPRT gene expression for each condition. Acute hypoxia 
(2.5% 02; 4 hours- "AH") was used as a positive control for the induction of transcripts. Data in graphs represent the mean +/- 
S.E.M. from three separate experiments with a sample size of 3–5 with representative gels above each graph. Asterisk, P < 0.05; 
double asterisk, P < 0.01; triple asterisk, P < 0.001 as compared to cells incubated in three weeks of normoxia (21%02) (N) 
(dashed line).
oxygen. UCP, APO and L-NAME had little effect on the
"memory" of GLUT-1 protein induction (Figure 7G)
whereas OXY resulted in a partial but significant interrup-
tion of GLUT-1 induction.
Persistent changes in HIF-1α ubiquitylation in response to 
chronic mild decreased oxygen
To begin to explore the mechanistic basis behind the sta-
bilization of the HIF-1α protein after oxygen normaliza-
tion, the ubiquitylation of HIF-1α was examined in
response to mild decreased oxygen. Using immunoprecip-
itation (IP) against HIF-1α and a Western blot against
ubiquitin (Figure 8; top blot), it was found that chronic
mild decreased oxygen (D) resulted in decreased ubiquit-
ylation of HIF-1α while normalization of oxygen for one
week after two weeks mild decreased oxygen (D>N)
resulted in similar levels of ubiquitylation as cells exposed
to normoxia (N). These ubiquitin blots were then re-Page 7 of 13
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(Figure 8; middle blots), and the densitometry of bands
graphed as a ratio of ubiquitin:HIF-1α (Figure 8; bottom
graph). It was found that chronic exposure to mild
decreased oxygen, and to a lesser extent mild decreased
oxygen followed by one week of oxygen normalization
resulted in significantly decreased ubiquitin/HIF-1α ratios
(Figure 8; bottom graph).
Discussion
The present study demonstrates proof-of-principle that
chronic exposure to mild decreased oxygen is capable of
stimulating HIF signaling and that this induction of sign-
aling persists one week after oxygen levels are normalized.
We found this "memory" of HIF signaling was not cell
type-specific, being observed in two different endothelial
cell types as well as in aortic SMCs. We found that degrad-
ing the HIF-1α protein using the chemical YC-1 was capa-
ble of interrupting the "memory" of HIF-1α, VEGF,
BNIP3, PAI-1 and iNOS induction and that decreasing cel-
lular reactive species using a general antioxidant or an
inhibitor of xanthine oxidoreductase was capable of inter-
rupting the "memory" of GLUT-1 induction. Finally, we
found that levels of ubiquitylated HIF-1α were reduced in
response to chronic mild decreased oxygen and only par-
tially recovered after oxygen levels were normalized. As a
result of these findings, we speculate that HIF signaling
may be contributing to the pathogenesis of endothelial
dysfunction and could be further explored be a therapeu-
tic target in addition to oxygen normalization.
The 15% O2 used in these studies is likely the mildest
decrease in oxygen resulting in an induction of HIF sign-
aling. This finding suggests that even such "innocuous"
decreases in oxygen levels can trigger a hypoxic-like
response in the endothelium. This could be a double-
edged sword in terms of propagating endothelial dysfunc-
tion. Although purely speculative at this point, the persist-
ent increase in GLUT-1 after oxygen normalization could
result in increased glucose transport into the endothe-
lium, which could exacerbate endothelial dysfunction in
diabetic patients. The persistent induction of iNOS after
Effect of oxygen normalization on expression of HIF-1α, HIF-2α, VEGF, and GLUT-1 protein expression in HUVECs and ASMCsFigure 5
Effect of oxygen normalization on expression of HIF-1α, HIF-2α, VEGF, and GLUT-1 protein expression in 
HUVECs and ASMCs. HUVECs (A-D) and human ASMCs (E-H) were exposed as described in Figure 1. Western blots 
were performed against HIF-1α (A and E), HIF-2α (B and F), GLUT-1 (D-H) on cellular lysates and ELISA was performed 
against VEGF (C and G) on cellular supernatants. Graphs indicate the densitometric analysis relative to the respective nor-
moxic protein expression (dashed line) with a representative blot for each protein above each graph. Acute hypoxia (2.5% 02; 
4 hours – "AH") was used as a positive control for the induction of each of the target protein. Data in graphs represent the 
mean +/- S.E.M. from three separate experiments with a total sample size of 4–6 and with representative gels above each 
graph. Asterisk, P < 0.05; double asterisk, P < 0.01; triple asterisk, P < 0.001 as compared to cells incubated in normoxia for 
three weeks.Page 8 of 13
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vasodilation, but more likely the excess NO would com-
bine with reactive oxygen species to form reactive nitrogen
species, and again could worsen endothelial dysfunction
[59]. The "memory" of VEGF induction after oxygen nor-
malization could also be a double-edged sword, with the
appropriate amount of VEGF facilitating neovasculariza-
tion and an excess of VEGF leading to ill-formed vessels
[60] and to increased vascular permeability and leukocyte
infiltration [61]. Finally, high levels of PAI-1 have been
found to be associated with cardiovascular disease [62],
and BNIP3 has been found to be a mediator of myocardial
death after infarction [63], again allowing one to surmise
that the induction of these two HIF target genes could
affect endothelial dysfunction.
In this work, both HIF α subunits were found to respond
similarly to chronic mild decreased oxygen exposure,
however, a "memory" of HIF-1α, but not HIF-2α was
observed after one week of normalized oxygen levels fol-
lowing two weeks of mild decreased oxygen in both the
microvascular (Figure 3) and umbilical vein (Figure 5)
endothelial cells. In the aortic smooth muscle cells, how-
ever, a "memory" of HIF-2α protein induction was
observed (Figure 5). This suggests, as others have implied,
a differential regulation of these two HIF α subunits in
response to certain stressors and in specific cell types
[64,65,63,66]. This also supports the predominance of
HIF-1α as compared to HIF-2α in some systems for regu-
lating gene expression in response to decreased oxygen
[67-69,66,62,64,70]. Although not examined in these
studies, a decrease the endogenous HIF inhibitor HIF-3α
[18] could also explain the cellular "memory" of HIF
induction and ongoing studies in our laboratory are
directed toward understanding the role of this protein in
response to chronic mild decreased oxygen.
The "memory" of GLUT-1 induction after oxygen normal-
ization was found to be mediated at least in part by reac-
tive species, with an inhibitor of reactive species
production through xanthine oxidoreductase resulting in
a significant interruption of GLUT-1 "memory" (Figure
7G). This finding is supported by the work of Kelley et al.
[70], who found that moderate hypoxia (10% O2)
resulted in the induction of xanthine oxidoreductase in
endothelial cells. An alternative to explain the cellular
"memory" HIF induction could be that the re-oxygenation
itself is stimulating HIF, perhaps via an increase in reactive
species. While the addition of reactive species inhibitors
and scavengers during the oxygen normalization period
(Figure 7G) appears to rule this out in all cases except per-
haps GLUT-1, this would be another interesting area of
exploration. The addition of reactive species donors or
other compounds like pro-inflammatory cytokines which
increase reactive species together with the measurement of
reactive species markers like 3-nitrotyrosine [71] and
esterified glutathione [20] could be used to further
address these issues.
The canonical mechanism of HIF induction in response to
hypoxia, however, is not through reactive species but
rather through HIF prolyl hydroxylase (HPH), enzymes,
which target HIF α subunits for ubiquitylation and ulti-
mate degradation by the proteasome and which are ren-
dered inactive in response to low oxygen [72]. Based on
many previous reports, it seemed improbable that the
mild decreased oxygen (15% O2) used in this study is low
enough to act through this mechanism [22, 72, 73]. Our
results with ubiquitylated HIF-1α (Figure 8), however,
suggest that HIF-1α ubiquitylation is reduced in response
to chronic mild decreased oxygen and that ubiquitylation
Effect of adenoviral siRNA on HIF-1α protein (A) and cell proliferation (B) in HMEC-1 cellsFigure 6
Effect of adenoviral siRNA on HIF-1α protein (A) and 
cell proliferation (B) in HMEC-1 cells. Adenoviral vec-
tors containing hairpin siRNAs against HIF-1α were created 
as in the methods. Panel A. HMEC-1 cells were infected with 
50–100 PFU/cell adenovirus or 5 μM YC-1, exposed to 5% 
O2 for 48 hours then cell lysates made and HIF-1α protein 
expression assessed by Western blot. Representative bands 
for HIF-1α are shown. Panel B. HMEC-1 cells were infected 
with adenovirus or treated with 5 μM YC-1 every 3 days for 
7 days and cell proliferation assessed using the CFDA-AM 
assay as in methods. The data represent the mean +/- SEM of 
triplicate wells from 3 independent experiments. *** = P < 
0.001 using one-way ANOVA with a Neuman-Keuls multiple 
comparisons post-test.Page 9 of 13
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Effect of various inhibitors and anti-oxidants on "memory" for HIF-1α, HIF-2α, Glut-1, BNIP3, PAI-1, iNOS and VEGF expres-sion in human endothelial cellsFigure 7
Effect of various inhibitors and anti-oxidants on "memory" for HIF-1α, HIF-2α, Glut-1, BNIP3, PAI-1, iNOS 
and VEGF expression in human endothelial cells. HUVECs were exposed to two weeks of mild decreased oxygen fol-
lowed by one weeks of normoxia (D→N) in the presence or absence of 5 μM of the HIF inhibitor YC-1, or 62.5 μM α-lipoic 
acid (ALA), or 25–100 PFU/cell UCP2 adenovirus, or 10 μM apocynin (APO), or 10 μM oxypurinol (OXY) or to 1 mM L-
NAME. Western blots were performed against HIF-1α (A), HIF-2α (B), BNIP3 (D), PAI-1 (E), iNOS (F) and GLUT-1 (G) on 
cellular lysates and ELISA was performed against VEGF (C) on cellular supernatants. Graphs for each Western blot indicate the 
densitometric analysis relative to the respective "memory" (D→N) protein expression (dashed line). Data in graphs represent 
the mean +/- S.E.M. from three separate experiments with a total sample size of 4–6 and with representative gels above each 
graph. Double asterisk, P < 0.01; triple asterisk, P < 0.001 as compared to cells in "memory" (D→N) treatment.
BMC Cardiovascular Disorders 2007, 7:4 http://www.biomedcentral.com/1471-2261/7/4only partially recovers one week after oxygen levels were
normalized. Ongoing work in our laboratory is seeking to
examine whether the modification of HIF-1α by HPHs or
whether the ubiquitylation of hydroxylated HIF-1α is the
target for HIF stabilization in response to chronic mild
decreased oxygen and upon oxygen normalization.
Conclusion
In summary, our results provide a proof-of-principle that
hypoxic signaling through HIF is induced in response to
chronic mild decreased oxygen and that this induction
persists long after oxygen levels are normalized. This work
implies that the HIF system could be a relevant therapeu-
tic target in the treatment of endothelial dysfunction. This
work also upholds and extends a possible role of reactive
species in the formation of endothelial dysfunction and
bolsters the use of antioxidants and xanthine oxidoreduct-
ase inhibitors in the treatment of vascular disease in addi-
tion to oxygen normalization.
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